News Concentra throws lifeline to troubled CARGO Therapeutics After cutting staff and halting development of its CAR-T therapies, CARGO has agreed to a takeover by Kevin Tang's Concentra Bio.
News CARGO offloads staff after abandoning lead CAR-T Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
News CARGO eyes $300m IPO against lacklustre listings backdrop CARGO Therapeutics has said it plans to offer around 18.8 million shares in the latest bid by a biotech to list on the Nasdaq, amid a desultory year for initial public off
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.